Study #2024-1050
A phase 2 multiple dose study to evaluate the efficacy and safety of PUl-042 inhalation solution in reducing lower respiratory tract complications in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation (HSCT) with documented viral infections with parainfluenza virus (PIV), human metapneumovirus (HMPV) or respiratory syncytial virus (RSV)
MD Anderson Study Status
Enrolling
Treatment Agent
PUL-042, Placebo
Description
The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral infections due to PIV, hMPV, or RSV. PUL-042 or a placebo will be administered 3 times over a 6-day period. The total duration of the study will be approximately 30 days.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
Study phase:
Phase II
Physician name:
Amy Spallone
Department:
Infectious Diseases
For general questions about clinical trials:
1-855-807-2462
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.